Cataract extraction better with ECP

Article

Endoscopic cyclophotocoagulation (ECP) and phacoemulsification cataract extraction, when combined, result in greater reduction of IOP and need for IOP-lowering medications over 3 years compared with cataract extraction by itself.

Endoscopic cyclophotocoagulation (ECP) and phacoemulsification cataract extraction, when combined, result in greater reduction of IOP and need for IOP-lowering medications over 3 years compared with cataract extraction by itself. That's according to a study by Brian A. Francis, MD, and colleagues recently published in theJournal of Cataract & Refractive Surgery.

"ECP is the first and most proven MIGS (micro-invasive glaucoma surgery). This study confirms our belief that ECP is a safe and effective adjunct to cataract surgery," said Dr Stanley J. Berke, one of the authors. "The results are encouraging from a clinical standpoint, demonstrating that by addressing glaucoma and cataract simultaneously, we are not only lowering IOP but also reducing the need for glaucoma medications, which results in reducing costs, burden, and side effects to patients."

Researchers studied 80 patients whose eyes had medically controlled open-angle glaucoma and visually significant cataract. The number of glaucoma medications they needed decreased from 1.5 ± 0.8 to 0.4 ± 0.7 (at 1 year and 2 years, respectively). At the 3-year mark, the number of medications required decreased to –0.1 ± 0.8 (n = 45). Mean IOP decreased from 18.1 mmHg ± 3.0 at baseline to 16.0 ± 2.8 mmHg at 1 year, 16.0 ± 3.3 mmHg at 2 years, and 15.4 ± 2.5 at 3 years.

Most eyes that had undergone cataract extraction alone required the same number of medications as previously used or had to use more medications over the long term. Additionally, researchers found that "adding ECP did not increase the risk for serious complications compared with cataract extraction alone."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
© 2025 MJH Life Sciences

All rights reserved.